logo
Plus   Neg
Share
Email

Sanofi: Libtayo Shows Clinically-Meaningful And Durable Responses In Skin Cancer

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced topline data from a pivotal, single-arm, open-label trial for the PD-1 inhibitor Libtayo in patients with advanced basal cell carcinoma who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy.

Libtayo demonstrated clinically meaningful and durable responses in Second-line Advanced Basal Cell Carcinoma. Regeneron and Sanofi plan regulatory submissions in 2020.

Basal Cell Carcinoma is a skin cancer and is the most common cancer worldwide, with approximately two million new cases diagnosed every year in the U.S. alone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has unveiled Instagram Reels as its answer to the popular Chinese-owned video app TikTok. The social media giant said in a blog post that Instagram Reels is a new way to create short, entertaining videos on Facebook's photo-sharing app Instagram. Facebook reportedly shut down its TikTok clone Lasso in July, ahead of the launch of Instagram Reels. WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation. Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020.
Follow RTT